Literature DB >> 9164956

Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.

K Sarkar1, P K Das.   

Abstract

Active targeting of muramyl dipeptide (MDP) to macrophages was studied by conjugation with the neoglycoprotein, mannosyl human serum albumin (mannose-HSA) using visceral leishmaniasis as the model macrophage disease. Conjugation did not decrease the affinity of the neoglycoprotein for macrophage mannose receptor. Mannose-HSA-MDP was 50 times more efficient than free MDP in inhibiting the growth of Leishmania donovani inside peritoneal macrophages. Moreover, in a 60-day murine model of visceral leishmaniasis, 95% of the spleen parasite burden was reduced by mannose-HSA-MDP at a dose of 0.5 mg/kg/day given for 4 days. Free MDP at a similar dose had very little effect. In vitro exposure of MDP caused enhanced generation of O2- by macrophages, whereas generation of nitric oxide (NO) was not induced. The elevated antileishmanial activity of MDP-treated macrophages in culture was abrogated by O2- scavengers. In contrast, considerably enhanced amounts of NO and O2- were generated from macrophages of mannose-HSA-MDP-treated animals, and their splenocytes secreted soluble factors providing all the signals required for the induction of NO biosynthesis. The increase in NO production was paralleled by a concomitant increase in antileishmanial activity, which was reversed by NO synthesis inhibitors. Splenocyte supernatants treated with anti-IFN-gamma or anti-TNF-alpha Abs suppressed inducible NO generation by macrophages. Moreover, i.v. administration of anti-IFN-gamma and anti-TNF-alpha along with mannose-HSA-MDP greatly reduced protection against L. donovani infection. Neoglycoprotein-conjugated MDP, therefore, activated mouse macrophages in vivo to kill L. donovani, and this may depend on the physiologic generation of NO induced by IFN-gamma and TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9164956

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Modulating immunity as a therapy for bacterial infections.

Authors:  Robert E W Hancock; Anastasia Nijnik; Dana J Philpott
Journal:  Nat Rev Microbiol       Date:  2012-03-16       Impact factor: 60.633

2.  Immunomodulatory peptide from cystatin, a natural cysteine protease inhibitor, against leishmaniasis as a model macrophage disease.

Authors:  Snigdha Mukherjee; Anindita Ukil; Pijush K Das
Journal:  Antimicrob Agents Chemother       Date:  2007-03-05       Impact factor: 5.191

3.  Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation.

Authors:  Keerti Jain; Ashwni Kumar Verma; Prabhat Ranjan Mishra; Narendra Kumar Jain
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

4.  Isolation of a laminin-binding protein from the protozoan parasite Leishmania donovani that may mediate cell adhesion.

Authors:  A Ghosh; K Bandyopadhyay; L Kole; P K Das
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

5.  Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections.

Authors:  Sandra Redlich; Sandra Ribes; Sandra Schütze; Roland Nau
Journal:  J Neuroinflammation       Date:  2014-06-14       Impact factor: 8.322

6.  Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis.

Authors:  Gul Shahnaz; Benson J Edagwa; JoEllyn McMillan; Sohail Akhtar; Abida Raza; Naveeda A Qureshi; Masoom Yasinzai; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2016-11-23       Impact factor: 5.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.